MRK - Merck & Co., Inc.
| Previous Close | 79.43 |
| Open | 79.18 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 2200 |
| Day's Range | 79.15 - 80.03 |
| 52 Week Range | 52.83 - 80.19 |
| Volume | 7,386,114 |
| Avg. Volume | 13,048,044 |
| Market Cap | 207.588B |
| Beta (3Y Monthly) | 0.38 |
| PE Ratio (TTM) | 34.41 |
| EPS (TTM) | 2.32 |
| Earnings Date | Apr 30, 2019 |
| Forward Dividend & Yield | 2.20 (2.78%) |
| Ex-Dividend Date | 2019-03-14 |
| 1y Target Est | 82.81 |
- PR Newswire•13 hours ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp.
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning ...
- GlobeNewswire•17 hours ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
- Benzinga•17 hours ago
Merck To Buy Immune Design For $300M
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
- Zacks•18 hours ago
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
- PR Newswire•19 hours ago
Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp. (NASDAQ: IMDZ) ("Immune ...
- Reuters•20 hours ago
Merck to buy immunotherapy developer Immune Design for $300 mln
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
- Business Wire•20 hours ago
Merck to Acquire Immune Design
Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of MRK earnings conference call or presentation 1-Feb-19 1:00pm GMT
Q4 2018 Merck & Co Inc Earnings Call
- Zacks•2 days ago
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks•2 days ago
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
- Zacks•2 days ago
Intercept Reports Positive Top-Line Data for NASH, Shares Up
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
- American City Business Journals•2 days ago
Merck expands Mass. reach with Torque cancer collaboration
In a collaboration announced Tuesday, Keytruda will be tested with Torque's T-cell therapy against several cancers.
- TheStreet.com•2 days ago
Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial
shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration. Merck said late Tuesday that its Keytruda treatment for patients with advanced liver cancer who were previously treated with systemic therapy did not meet the endpoints for overall survival when compared with placebo plus best supportive care. "While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings from the Phase 2 study, which led to the accelerated approval of KEYTRUDA for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib," said chief medical officer Dr. Roy Baynes.
- Benzinga•2 days ago
The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
- GlobeNewswire•2 days ago
New Research: Key Drivers of Growth for DISH Network, Avon Products, Merck & Co., Laredo Petroleum, Health Insurance Innovations, and Bruker — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 days ago
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC)
Marks First Application for KEYTRUDA in SCLC
- GuruFocus.com•2 days ago
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10. ...
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 135,613 shares of MRK on 02/19/2019 at an average price of $80.03 a share.
- Reuters•2 days ago
Merck's Keytruda fails late-stage study in liver cancer patients
Merck & Co Inc's cancer drug Keytruda failed a late-stage trial's main goals of slowing disease progression and extending the life of patients with a common type of liver cancer, the company said on Tuesday. The results could hamper prospects for the drug, which had received an accelerated approval from the U.S. Food and Drug Administration in November as a treatment for patients with advanced liver cancer who had been previously treated with Bayer AG's Nexavar. Keytruda, which is approved to treat several forms of cancer including skin and lung cancer, is Merck's biggest drug and brought in revenue of $7.17 billion last year.
- MarketWatch•2 days ago
Merck stock falls in late trading on cancer study
Merck & Co. Inc. shares declined in after-hours trading Tuesday after the company announced that a study of its Keytruda drug did not meet its goals. The company said that a study on the effectiveness of the drug for patients with a specific type of liver cancer did not reach its defined goals for survival. Merck is testing the drug on a variety of cancers in a big bet on immunotherapy for cancer. Merck shares dipped slightly more than 1% in the extended session after making the announcement, following a 0.7% decline in the regular session. The stock has gained 40.8% in the past 12 months as the S&P 500 index has gained 1.6%.
- Business Wire•2 days ago
Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Merck , known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival ...
- Zacks•3 days ago
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
- Markit•3 days ago
See what the IHS Markit Score report has to say about Merck & Co Inc.
Merck & Co Inc NYSE:MRKView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MRK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $10.04 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. MRK credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•3 days ago
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
A drug that disappointed in 2018 will get an unexpected dance at the big ball.
- Business Wire•3 days ago
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
U.S. Approval Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Phase 3 EORTC1325/KEYNOTE-054 Trial
- Simply Wall St.•4 days ago
A Look At The Fair Value Of Merck & Co., Inc. (NYSE:MRK)
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today I will be providing a simple run through ofRead More...
